Strain Name: |
FVB.Cg-Tg(ACTA1-cre)79Jme/J |
|---|---|
Stock Number: |
006139 |
Availability: | Repository-Cryopreserved |
Price and Supply Information | |
General Terms and Conditions |
| Genes & Alleles | ACTA1; cre; Tg(ACTA1-cre)79Jme; |
Product Information
Strain Details
Type JAX® GEMM® Strain - Congenic Additional information on JAX® GEMM® Strains. Type JAX® GEMM® Strain - Mutant Strain Type JAX® GEMM® Strain - Transgenic Species laboratory mouse Donating Investigator IMR Colony, The Jackson Laboratory Strain Description
Mice hemizygous for this HSA-Cre79 transgene are viable, fertile, normal in size, and do not display any gross physical or behavioral abnormalities. These HSA-Cre79 transgenic mice have the cre recombinase gene driven by the human alpha-skeletal actin (HSA or ACTA1) promoter. Cre activity is restricted to adult striated muscle fibers and embryonic striated muscle cells of the somites and heart. When bred with mice containing a loxP-flanked sequence of interest, Cre-mediated recombination will result in striated muscle-specific deletion of the flanked genome. Specifically, these HSA-Cre79 (or ACTA1-Cre) transgenic mice were originally used to breed with mice heterozygous for a deletion of exon 7 and a loxP-flanked exon 7 mutation on homologous chromosomes of the Smn1 gene (see Stock No. 006138 or Stock No. 006146). The resulting offspring (heterozygous for the deletion in all cells and homozygous for the deletion in striated muscle cells) have extremely reduced lifespan characterized by progressive muscle necrosis and paralysis, and represent a model of spinal muscular atrophy (SMA). Additional SMA strains expressing cre in neurons are available as well (see Stock No. 005938, Stock No. 006297, and Stock No. 006663).HSA-Cre79 transgenic mice are available on different genetic backgrounds (see Stock No. 005936, Stock No. 006139, and Stock No. 006149). In an attempt to offer alleles on well-characterized or multiple genetic backgrounds, alleles are frequently moved to a genetic background different from that on which an allele was first characterized. It should be noted that the HSA-Cre79 phenotype could vary from that originally described on a mixed genetic background. We will modify the strain description if necessary as published results become available.
Importation of this model was supported by the Spinal Muscular Atrophy Foundation. Creation and development was supported by the National Institute of Health and Medical Research of France (Inserm) and the Association Française contre les Myopathies (AFM). An additional help was provided by Families of SMA (U.S.A.) and Andrew’s Buddies (U.S.A.).
Strain Development
A targeting vector was designed to place a cre recombinase gene (preceded by the rabbit beta-globin intron and followed by the SV40 polyadenylation signal) under control of the human alpha-skeletal actin (HSA, ACTA1) promoter. This construct was microinjected into (C57BL6 x SJL)F1 embryos and implanted into pseudopregnant CD1 foster mothers. Founder 79 was bred to C57BL/6 to generate transgenic mice. At different points while maintaining this strain, transgenic mice were bred with C57BL/6 wildtype mice and/or mice harboring a loxP-flanked exon 7 mutation (Smn1tm1Jme or SMNF7) on a C57BL/6 and "129Sv" mixed background. Because expression of this transgene is confined to muscle tissue, Cre-mediated deletion of the “floxed” exon does not occur in the germline. Thus, offspring contained either the wildtype Smn1 locus or the “floxed” locus; never the Smn1 deletion. Transgenic offspring bearing the wildtype Smn1 locus on this mixed (but predominantly B6;129) background were sent to The Jackson Laboratory by Dr. Judith Melki in April 2006. After arriving, mutant mice were backcrossed to FVB/NJ (Stock No. 001800) for 5-10 generations.
Gene & Allele Details
| Allele Symbol | Tg(ACTA1-cre)79Jme | ||
|---|---|---|---|
| Allele Name | transgene insertion 79, Judith Melki | ||
| Common Name(s) | HSA-Cre; HSA-Cre79; HSA::cre; | ||
| Mutation Made By | Judith Melki, Genopole, Inserm U798 | ||
| Strain of Origin | (C57BL/6J x SJL)F1 | ||
| Site of Expression | adult striated muscle fibers and embryonic striated muscle cells of the somites and heart | ||
| Expressed Gene | cre, cre recombinase, bacteriophage P1 | ||
| Cre recombinase is an enzyme derived from the bacteriophage P1 that specifically recognizes loxP sites. Cre has been shown to effectively mediate the excision of DNA located between loxP sites. After the excision event, the DNA ends recombine leaving a single loxP site in place of the intervening sequence. | |||
| Promoter | ACTA1, actin, alpha 1, skeletal muscle, human | ||
| Molecular Note | This transgene expresses Cre recombinase under the control of a human alpha-skeletal actin promoter, active in striated muscle, heart, and skeletal muscle. [MGI Ref ID J:67906] | ||
Control Information
| Control | ||
|---|---|---|
| Noncarrier | ||
| 001800 FVB/NJ | ||
| Considerations for Choosing Controls | ||
| Control Pricing Information for JAX® GEMM® Strains | ||
Genotyping Protocols
Generic Cre
Colony Maintenance
| Breeding & Husbandry | After arriving at The Jackson Laboratory on a mixed background, mutant mice were bred to wildtype FVB/NJ (Stock No. 001800) for 5-10 generations. The resulting backcrossed hemizygotes were maintained thereafter by breeding transgenic mice to either wildtype siblings from the colony or FVB/NJ. |
|---|
Related Strains
Strains carrying Tg(ACTA1-cre)79Jme allele
006149 B6.Cg-Tg(ACTA1-cre)79Jme/J 005936 STOCK Tg(ACTA1-cre)79Jme/J View Strains carrying Tg(ACTA1-cre)79Jme (2 strains)
Additional Web Information
Congenic Nomenclature
Cre-lox or FLP-FRT Systems
Research Applications
This mouse can be used to support research in many areas including:
cre relatedNeurobiology Research
Neurodegeneration
Neuromuscular Defects
Spinal Muscular Atrophy (SMA)
Research Tools
Cre-lox System (Cre-Recombinase Expression: Germline/Embryonic Expression)
Genetics Research (Mutagenesis and Transgenesis: Cre-lox System)
Neurobiology Research
Research Tools
Cre-lox System
Genetics Research (Mutagenesis and Transgenesis: Cre-lox System)
References
Selected Reference(s)
Additional ReferencesMiniou P; Tiziano D; Frugier T; Roblot N; Le Meur M; Melki J. 1999. Gene targeting restricted to mouse striated muscle lineage. Nucleic Acids Res 27(19):e27. [PubMed: 10481039] [MGI Ref ID J:67906]
Price and Supply Information
| Strain Name: | FVB.Cg-Tg(ACTA1-cre)79Jme/J |
| Stock Number: | 006139 |
Price Details
IMPORTANT NOTE: Prices are based on shipping destination. The shipping destinations are:
- USA, Canada and Mexico
- International
*Pricing for Shipping Destination selected:
International
| Price(s) in US dollars ($) | |||||
|---|---|---|---|---|---|
| Cryorecovery Fee | $2470.00 | ||||
Supply Details
| Standard Supply | Repository-Cryopreserved. Must Be Recovered. Please refer to pricing and supply notes for further information. |
|---|---|
| Supply Notes |
Cryorecovery - Standard. The recovery process begins when a signed agreement form is returned to the Customer Service Department after order placement. Although results vary by strain, at least two males and two females (two pairs) will be provided, typically within 15 weeks of our receipt of the signed agreement form. If the first recovery attempt is unsuccessful or only one pair is recovered, a second recovery will be done, extending the delivery time to approximately 25 weeks. At least one member of each pair will be of known genotype and will carry the mutation if it is a mutant strain. Please note that pairs may not reflect the mating scheme utilized by The Jackson Laboratory prior to cryopreservation of the strain. Mating schemes are sometimes modified for successful cryopreservation. Price represents a repository maintenance fee, which includes the cost of recovery of the strain from the cryopreservation resource and the periodic replacement of the frozen embryos used for recovery. Cryorecovery to establish a Dedicated Supply for greater quantities of mice. |
| Licensing | See General Terms and Conditions below for Licensing and Use Restrictions |
| Control Information | View Control Information in Strain Details. View Control Pricing Information for JAX® Strains. |
General Terms and Conditions
View JAX® Mice & Services Conditions of Use.
Effective September 26, 2007: License Requirements for Strains using Cre-lox Technology only apply in Canada, see Licenses for Strains using Cre-lox Technology.
The Jackson Laboratory's Genotype Promise
The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.Ordering and Purchasing Information
Purchasing Information
JAX® Mice Orders
Surgical Services
Contact Information
Orders & Technical Support
Tel: 800.422.6423 or 207.288.5845
Fax: 207.288.6150
Technical Support Email Form